ADC Therapeutics S.A. logo ADCT - ADC Therapeutics S.A.

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY 0
BUY 5
HOLD 6
SELL 1
STRONG
SELL 0
| PRICE TARGET: $3.50 DETAILS
HIGH: $5.00
LOW: $2.00
MEDIAN: $3.50
CONSENSUS: $3.50
UPSIDE: 102.31%

Stock News

ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements

ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements

$86.6 Million Private Placement announced, with participation from new and existing investors, extending expected cash runway into 2029  HealthCare Royalty financing agreement amended, removing change-of-control payment  Senior secure loan refinanced, decreasing principal to $50M with bullet payment in August 2029 and no minimum liquidity LAUSANNE, Switzerland, Oct. 8, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced a comprehensive strategic financial restructuring designed to strengthen its balance sheet, reduce leverage, and increase strategic optionality to maximize shareholder value while extending the expected cash runway into 2029. The strategic initiative includes securing new equity financing, restructuring the HealthCare Royalty (HCR) agreement, and reducing the outstanding loan principal.

Oct 08, 2026 05:00 AM • prnewswire.com
ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026 LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASH Company evaluating regulatory path for ZYNLONTA® to obtain full approval and advance into earlier lines of DLBCL following LOTIS-5 pre-sBLA meeting Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, Aug. 13, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter ended June 30, 2026, and provided recent operational updates.

Aug 13, 2026 03:30 AM • prnewswire.com
ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

LAUSANNE, Switzerland, Aug. 6, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Thursday, August 13, 2026, at 8:30 a.m. EDT to report financial results for the second quarter of 2026 and provide operational updates.

Aug 06, 2026 03:30 AM • prnewswire.com
ADC Therapeutics Announces New Employee Inducement Grant

ADC Therapeutics Announces New Employee Inducement Grant

LAUSANNE, Switzerland, July 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company's common shares to a new employee on July 1, 2026 ("Grant"). The Grant was offered as material inducement to the employee's employment.

Jul 01, 2026 12:05 PM • prnewswire.com
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial

ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial

100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamab Full data expected in fourth quarter of 2026 LAUSANNE, Switzerland, June 30, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (r/r DLBCL). LOTIS-7 trial enrollment is now complete with 100 r/r DLBCL patients dosed at the selected 150 µg/kg dose of ZYNLONTA plus glofitamab.

Jun 30, 2026 03:15 AM • prnewswire.com
ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities

ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities

Planned ~17% workforce reduction expected to generate annualized estimated savings of approximately $10M, enhancing financial flexibility Company focused on delivering upcoming regulatory and clinical milestones, including planned LOTIS-5 sBLA submission and full LOTIS-7 data by end of 2026 LAUSANNE, Switzerland, June 24, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced a strategic reorganization to focus resources behind key value-driving initiatives in support of the ZYNLONTA® (loncastuximab tesirine-lpyl) franchise. As part of the reorganization, ADC Therapeutics plans to reduce its workforce globally by approximately 17 percent.

Jun 24, 2026 03:30 AM • prnewswire.com

Price Targets